TCGA-BH-A1EO-01A-11R-A137-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 93
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-46-3767-01A-01R-0980-07 | — | cohortSQ1 | 0.919 |
| 2 | TCGA-A2-A0T6-01A-11R-A084-07 | — | A | 0.909 |
| 3 | TCGA-AR-A24O-01A-11R-A169-07 | — | A | 0.901 |
| 4 | TCGA-44-6774-01A-21R-1858-07 | — | cohortA1 | 0.894 |
| 5 | SRR35579817 | — | A | 0.888 |
| 6 | TCGA-60-2704-01A-11R-2045-07 | — | cohortSQ1 | 0.887 |
| 7 | TCGA-E9-A1NG-01A-21R-A14M-07 | — | A | 0.887 |
| 8 | fd618c1b-e230-408d-aed8-4ad6df3fc4e6 | — | — | 0.886 |
| 9 | 69842b4c-448a-4275-8250-7b31948c56ec | — | — | 0.883 |
| 10 | SRR6013569 | — | cohortMD2 | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.570 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |